Výsledky vyhledávání - "Martin I. Freed"

Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans

Autor: Prasoon Chaturvedi, Erica Evans, Russell Karp, Matthew T. Labenski, Heather Lounsbury, Martin I. Freed, Steven Richard Witowski, Hormoz Mazdiyasni, Richland Wayne Tester, M. Nacht, Sharon Aslanian, Michael Sheets, Russell C. Petter, Juswinder Singh, Zhendong Zhu, Alex Dubrovskiy, William F. Westlin

Publikováno v: Journal of Pharmacology and Experimental Therapeutics. 346:219-228

Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies. Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development and activation through the BCR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d61db1f19445091f3dba37c82d79cc38
https://doi.org/10.1124/jpet.113.203489

Zobrazit plný text záznamu

Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes

Autor: John M. Lachin, Steven E. Kahn, Bernard Zinman, Dahong Yu, Rury R. Holman, Giancarlo Viberti, Barbara G. Kravitz, Nigel P. Jones, M. Colleen O’Neill, Martin I. Freed, Steven M. Haffner, William H. Herman

The inflammatory factor C-reactive protein (CRP) and the fibrinolytic variables fibrinogen and plasminogen activator-1 (PAI-1) are associated with long-term cardiovascular morbidity. To determine the contribution of body adiposity (BMI), insulin sens

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f3a1bf06495ced80befab1c0f5155e9
https://doi.org/10.2337/db06-0116

Zobrazit plný text záznamu

A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease

Autor: Peter A, LeWitt, Robert A, Hauser, Donald G, Grosset, Fabrizio, Stocchi, Marie-Helene, Saint-Hilaire, Aaron, Ellenbogen, Mika, Leinonen, Neil B, Hampson, Tia, DeFeo-Fraulini, Martin I, Freed, Karl D, Kieburtz

Publikováno v: Movement disorders : official journal of the Movement Disorder Society. 31(9)

Although levodopa is the most effective oral PD therapy, many patients experience motor fluctuations, including sudden loss of dose effect and delayed benefit. CVT-301 is a levodopa inhalation powder with the potential for rapid onset of action. The

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e90b44161d4b06474e7f621f85ad8b9c
https://pubmed.ncbi.nlm.nih.gov/27090868

Zobrazit plný text záznamu

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria

Autor: Luis M. Ruilope, L E Porter, Martin I. Freed, Wayde M. Weston, Heise Ma, George L. Bakris, Stephen O. McMorn

Publikováno v: Journal of Hypertension. 24:2047-2055

To test the hypothesis that rosiglitazone combined with metformin provides a greater reduction in microalbuminuria and blood pressure than metformin and glyburide at comparable levels of glycemic control.In a double-blind, parallel-group design 389 p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1522c6dc940471907b0fedc30b83f8b
https://doi.org/10.1097/01.hjh.0000244955.39491.88

Zobrazit plný text záznamu

Rosiglitazone reduces urinary albumin excretion in type II diabetes

Autor: Martin I. Freed, Heise Ma, L E Porter, George L. Bakris, Giancarlo Viberti, W M Weston

Publikováno v: Journal of Human Hypertension. 17:7-12

This study examines the effect of rosiglitazone on urinary albumin excretion (UAE) in patients with type II diabetes. Urinary albumin: creatinine ratio (ACR) was measured in a 52-week, open-label, cardiac safety study comparing rosiglitazone and glyb

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f8d1fdffd804d39d22e857124f90ca0
https://doi.org/10.1038/sj.jhh.1001444

Zobrazit plný text záznamu

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

Autor: Santica M. Marcovina, Margaret M Kreider, John D. Brunzell, Martin I. Freed, Nandita Biswas, Robert E. Ratner, Beth R Cohen

Publikováno v: The American Journal of Cardiology. 90:947-952

This study evaluated the effects of rosiglitazone therapy on lipids and the efficacy and safety of rosiglitazone in combination with atorvastatin in patients with type 2 diabetes mellitus. Three-hundred thirty-two patients entered an 8-week, open-lab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::810a15075f3aaa1ede47129f025e2a4e
https://doi.org/10.1016/s0002-9149(02)02659-0

Zobrazit plný text záznamu

A Diabetes Outcome Progression Trial (ADOPT)

Autor: William H. Herman, Bernard Zinman, John M. Lachin, Giancarlo Viberti, Martin I. Freed, Daniel Levy, Douglas A. Greene, Steven E. Kahn, Rury R. Holman, Nigel P. Jones, Heise Ma, Steven M. Haffner, Rhona A. Berry

Publikováno v: Diabetes Care. 25:1737-1743

OBJECTIVE—Therapies with metformin, sulfonylureas, or insulin improve glycemic control in the short term but do not prevent progressive islet β-cell failure or long-term deterioration in glycemia. Our goal was to evaluate, in patients recently dia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c6e93005d38d506fedb47e3a380714ab
https://doi.org/10.2337/diacare.25.10.1737

Zobrazit plný text záznamu

Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials

Autor: Harold E. Lebovitz, Martin I. Freed, Margaret M Kreider

Publikováno v: Diabetes Care. 25:815-821

OBJECTIVE—Troglitazone treatment has been associated with idiosyncratic hepatic reaction leading to hepatic failure and death in some patients. This raises questions regarding whether all thiazolidinediones or peroxisomal proliferator–activated r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5b9498a359d136ff7f20ec44e700c429
https://doi.org/10.2337/diacare.25.5.815

Zobrazit plný text záznamu

Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes

Autor: Elizabeth B. Rappaport, Martin I. Freed, Harold E. Lebovitz, Jo F. Dole, Rita Patwardhan

Publikováno v: The Journal of Clinical Endocrinology & Metabolism. 86:280-288

This study evaluated the efficacy and safety of rosiglitazone monotherapy in patients with type 2 diabetes. After a 4-week placebo run-in period, 493 patients with type 2 diabetes were randomized to receive rosiglitazone [2 or 4 mg twice daily (bd)]

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db019e3cbfbb760f366570777cb3a8cb
https://doi.org/10.1210/jcem.86.1.7157

Zobrazit plný text záznamu

Rosiglitazone Does Not Affect the Steady‐State Pharmacokinetics of Digoxin

Autor: Martin I. Freed, Robert A. Di Cicco, Scott D. Patterson, Ann K. Miller

Publikováno v: The Journal of Clinical Pharmacology. 40:1516-1521

Rosiglitazone is a potent insulin-sensitizing oral hypoglycemic agent of the thiazolidinedione class that works through activation of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) nuclear receptor and improves glycemic control in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::750890560463da0aeb05115402a1e6ea
https://doi.org/10.1177/009127000004001225

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání